By Katherine Hamilton
Soleno Therapeutics gained approval from the Food and Drug Administration for its hyperphagia drug.
The biopharmaceutical company focused on treating patients with rare diseases said Wednesday it got approval for Vykat XR, which is intended to treat hyperphagia in adults and children over four years old with Prader-Willi syndrome.
Prader-Willi syndrome is a genetic disorder. A hallmark of the disease is hyperphagia, an intense and persistent sense of hunger.
Soleno expects the drug to be available in April, it said.
The approval was based on a study and safety data from a comprehensive clinical development program.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 26, 2025 17:28 ET (21:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。